Keryx Biopharmaceuticals, Inc. Sustainability Profile
Keryx Biopharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2005, the company has made significant strides in developing innovative therapies for patients with kidney disease, particularly focusing on conditions such as chronic kidney disease and end-stage renal disease. Keryx is best known for its flagship product, Auryxia (ferric citrate), which uniquely addresses both iron deficiency and hyperphosphataemia in patients undergoing dialysis. This dual-action capability sets Keryx apart in a competitive market. With a commitment to improving patient outcomes, Keryx has established a strong market position, recognised for its contributions to renal health. The company continues to expand its operational reach, aiming to enhance the quality of life for patients globally.
DitchCarbon Score
How does Keryx Biopharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Keryx Biopharmaceuticals, Inc.'s score of 25 is lower than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Keryx Biopharmaceuticals, Inc.'s reported carbon emissions
Keryx Biopharmaceuticals, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Akebia Therapeutics, Inc., which may influence its climate commitments and reporting practices. As of now, Keryx Biopharmaceuticals has not established any documented reduction targets or initiatives related to carbon emissions. There are no commitments to the Science Based Targets initiative (SBTi) or other climate pledges that are publicly available. Given the lack of specific emissions data and reduction initiatives, it is unclear how Keryx Biopharmaceuticals is addressing climate change within its operational framework. The company may benefit from aligning with industry standards and setting measurable targets to enhance its sustainability profile in the biopharmaceutical sector.
How Carbon Intensive is Keryx Biopharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Keryx Biopharmaceuticals, Inc.'s Location?
Keryx Biopharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Keryx Biopharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
